D-0647-2020 Class II Terminated

Recalled by Akorn, Inc. — Lake Forest, IL

FDA drug recall D-0647-2020 was initiated by Akorn, Inc. on Nov 15, 2019 and is designated Class II. Reason for recall: Unit Dose Mispackaging: Customer complaint that a carton labeled as Myorisan 20 mg Capsules, USP erroneously contained one 10-count blister card of the 40 mg product in addition to two 10-count… The recall status is terminated (terminated Aug 9, 2022). Affected quantity: 4,206 boxes.

Recall details

Product Type
Drugs
Report Date
Jan 8, 2020
Initiation Date
Nov 15, 2019
Termination Date
Aug 9, 2022
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
4,206 boxes

Product description

MYORISAN (isotretinoin capsules, USP), 20mg, packaged in 30-count Capsules (3 x 10 Prescription Packs) per box, Rx only, Distributed by: VersaPharm Inc. - An Akorn Company, Lake Forset, IL 60045; NDC 61748-302-13.

Reason for recall

Unit Dose Mispackaging: Customer complaint that a carton labeled as Myorisan 20 mg Capsules, USP erroneously contained one 10-count blister card of the 40 mg product in addition to two 10-count blister cards of the 20 mg product.

Distribution pattern

Nationwide in the USA and Puerto Rico

Code information

Lot V20M54A, Exp 01/2021

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0647-2020
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0647-2020. Report a data issue: hello@regdatalab.com.